IN2012DN02860A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02860A
IN2012DN02860A IN2860DEN2012A IN2012DN02860A IN 2012DN02860 A IN2012DN02860 A IN 2012DN02860A IN 2860DEN2012 A IN2860DEN2012 A IN 2860DEN2012A IN 2012DN02860 A IN2012DN02860 A IN 2012DN02860A
Authority
IN
India
Prior art keywords
vaccine
vibrio cholerae
cell
lnaba
etec
Prior art date
Application number
Inventor
Jan Holmgren
Michael Lebens
Original Assignee
Gotovax Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gotovax Ab filed Critical Gotovax Ab
Publication of IN2012DN02860A publication Critical patent/IN2012DN02860A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/107—Vibrio
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

A vaccine against cholera and/or ETEC is provided, comprising a Vibrio cholerae O1 cell, characterized in that said cell comprises O1 antigens of both Ogawa and lnaba serotypes. Genetically modified Vibrio cholerae O1 cells for use in such vaccines, DNA-constructs for the modification, uses for the vaccine and methods of making a vaccine are also provided.
IN2860DEN2012 2009-09-16 2010-09-16 IN2012DN02860A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27235109P 2009-09-16 2009-09-16
PCT/SE2010/050996 WO2011034495A1 (en) 2009-09-16 2010-09-16 Vaccine against cholera and enterotoxigenic e. coli (etec) diarrhea

Publications (1)

Publication Number Publication Date
IN2012DN02860A true IN2012DN02860A (en) 2015-06-19

Family

ID=43758898

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2860DEN2012 IN2012DN02860A (en) 2009-09-16 2010-09-16

Country Status (15)

Country Link
US (1) US9511133B2 (en)
EP (1) EP2477649B1 (en)
JP (2) JP2013505017A (en)
KR (1) KR101722802B1 (en)
CN (1) CN102630166B (en)
AU (1) AU2010296065B2 (en)
CA (1) CA2774335C (en)
DK (1) DK2477649T3 (en)
ES (1) ES2616912T3 (en)
HU (1) HUE031957T2 (en)
IN (1) IN2012DN02860A (en)
PL (1) PL2477649T3 (en)
PT (1) PT2477649T (en)
WO (1) WO2011034495A1 (en)
ZA (1) ZA201202710B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
CN102824632A (en) * 2012-09-12 2012-12-19 北京民海生物科技有限公司 Polysaccharide conjugate vaccine of vibrio cholera group O1, preparation method and application thereof
RU2535122C1 (en) * 2013-11-06 2014-12-10 Федеральное казенное учреждение здравоохранения "Российский научно-исследовательский противочумный институт "Микроб" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека ("РосНИПЧИ "Микроб") Method for preparing choleragen anatoxin
RU2563620C2 (en) * 2014-08-05 2015-09-20 Федеральное казенное учреждение здравоохранения "Российский научно-исследовательский противочумный институт "Микроб" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека ("РосНИПЧИ "Микроб") Method for producing tabletted bivalent chemical cholera vaccine
KR20180096651A (en) * 2015-12-14 2018-08-29 엠에스디 웰컴 트러스트 힐레맨 랩스 피브이티. 리미티드 A novel method for producing purified recombinant cholera toxin B (rCTB) and its preparation
US10829522B2 (en) 2016-04-27 2020-11-10 Osaka University Peptide inhibiting colonization by pathogenic bacteria, and colonization inhibitor including same
US20210085775A1 (en) 2017-12-15 2021-03-25 Valneva Sweden Ab Methods and composition for preventing and/or treating cancer
WO2021005623A1 (en) * 2019-07-08 2021-01-14 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. A vaccine formulation for protection against enterotoxigenic e. coli (etec) and cholera
WO2021105061A1 (en) 2019-11-25 2021-06-03 Gotovax Ab Whole cell vaccines and methods of production thereof
CA3194598A1 (en) 2020-10-07 2022-04-14 Valentina SCREPANTI-SUNDQUIST Cholera vaccine formulation
WO2022117823A1 (en) * 2020-12-04 2022-06-09 Valneva Se Methods and compositions for preventing and/or treating autoimmune diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5882653A (en) * 1983-03-04 1999-03-16 The University Of Maryland System Vibrio cholerae 01 (CVD111) and non-01 (CVD112 and CVD112RM) serogroup vaccine strains, methods of making same and products thereof
US5330753A (en) * 1987-04-29 1994-07-19 President And Fellows Of Harvard College Cholera vaccines
AU4660893A (en) 1992-07-06 1994-01-31 President And Fellows Of Harvard College Deletion mutants as vaccines for cholera
US6203799B1 (en) * 1993-07-01 2001-03-20 Presidents And Fellows Of Harvard College Vibrio cholerae mutants which are soft-agar penetration defective and lack a functional CtxA subunit
JP3098401B2 (en) * 1995-07-12 2000-10-16 株式会社エルティーティー研究所 Formulation for nasal administration
WO2000067784A1 (en) * 1999-05-10 2000-11-16 University Of Maryland, Baltimore Bacteriophage isolated from bacterial genomes and extrachromosomal elements and methods of use thereof
US7270961B2 (en) * 2002-04-16 2007-09-18 Hui Sunny Chang In vitro assay for quantitating secreted antibodies in lymphocyte supernatant for evaluation of vaccine or antigen induced specific antibody secretion from ex vivo circulating antibody-secreting lymphocytes
US20060171966A1 (en) 2002-08-30 2006-08-03 Centre For Health And Population Research Variants of vibrio cholerae 01 biotype e1 tor with attributes of classical biotype
CU23334A1 (en) * 2003-03-20 2008-12-24 Inst Finlay VACCINE OF VIBRIO CHOLERAE INACTIVATED IN TABLETS
US20060099229A1 (en) * 2004-11-05 2006-05-11 Universiti Sains Malaysia Vibrio cholerae strains VCUSM1 and VCUSM4, method of producing same, and vaccine derivatives thereof
EP1543836A1 (en) * 2003-12-17 2005-06-22 Berna Biotech AG Recombinant Vibrio cholerae strain and vaccine comprising said strain
US8642046B2 (en) 2007-10-09 2014-02-04 Tufts University Cholera vaccines

Also Published As

Publication number Publication date
CN102630166B (en) 2015-08-05
JP2013505017A (en) 2013-02-14
JP2016074695A (en) 2016-05-12
CA2774335A1 (en) 2011-03-24
EP2477649B1 (en) 2016-11-23
WO2011034495A1 (en) 2011-03-24
EP2477649A4 (en) 2013-01-30
EP2477649A1 (en) 2012-07-25
ZA201202710B (en) 2015-12-23
AU2010296065A1 (en) 2012-05-10
US20120276146A1 (en) 2012-11-01
CN102630166A (en) 2012-08-08
AU2010296065B2 (en) 2015-05-21
PT2477649T (en) 2017-03-01
ES2616912T3 (en) 2017-06-14
PL2477649T3 (en) 2017-06-30
CA2774335C (en) 2016-10-18
KR20120081600A (en) 2012-07-19
US9511133B2 (en) 2016-12-06
JP6178384B2 (en) 2017-08-09
DK2477649T3 (en) 2017-03-06
KR101722802B1 (en) 2017-04-03
HUE031957T2 (en) 2017-09-28

Similar Documents

Publication Publication Date Title
IN2012DN02860A (en)
SG158154A1 (en) Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
WO2010111409A3 (en) Pluripotent stem cells
MY160201A (en) Immunostimulatory oligonucleotides
WO2006047515A3 (en) Dendritic cells loaded with heat shocked melanoma cell bodies
WO2012051211A3 (en) Antigen delivery platforms
EP1872793A4 (en) Polyamino acid for use as adjuvant
MX368220B (en) Novel adjuvant compositions.
IL215430A (en) Immunogenic compositions and vaccines for immunization against viruses and use thereof
HK1141812A1 (en) Vaccines based on targeting antigen to dcir expressed an antigen-presenting cells dcir
IL218447A0 (en) Co-culture lymphoid tissue equivalent (lte) for an artificial immune system (ais)
SG10201405442VA (en) Method and device for using oxygen in the steam reforming of biomass
IL193397A0 (en) Hpv antigens, vaccine compositions, and related methods
WO2010148334A3 (en) Generation of induced pluripotent stem cells from cord blood
WO2010000127A9 (en) Method to induce and expand therapeutic alloantigen- specific human regulatory t cells in large-scale
WO2009092005A3 (en) Methods of generating cardiomyocytes and cardiac progenitors and compositions
CA2763359C (en) New human rotavirus strains and vaccines
NZ715459A (en) A hyperbarically-inactivated microorganism, immunogenic compositions comprising same and methods for producing same
CL2011000913A1 (en) Stable and completely liquid combined vaccine comprising diphtheria, tetanus, whole cell pertussis antigens, and poliomyelitis virus and optionally one or more antigens selected from haemophilus influenzae and hepatitis; and manufacturing process.
WO2011069076A3 (en) Sustained release donepezil formulations
WO2010138750A3 (en) Generation of genetically corrected disease-free induced pluripotent stem cells
WO2008008541A3 (en) Methods to elicit, enhance and sustain immune responses against mhc class-i restricted epitopes, for prophylactic or therapeutic purposes
NZ607792A (en) Improved vaccine compositions
WO2010006326A3 (en) Methods and compositions for spore-based vaccines
WO2010110931A3 (en) Glycoconjugate vaccines